Results 121 to 130 of about 4,708 (131)

Efficacy and safety of tenofovir alafenamide versus tenofovir disoproxil fumarate in treatment‐naïve chronic hepatitis B

Liver International, 2022
Young-Suk Lim, Jihye Lim, Kang Mo Kim
exaly  

Blood immune cells from people with HIV on antiviral regimens that contain tenofovir alafenamide (TAF) and tenofovir disoproxil fumarate (TDF) have differential metabolic signatures

Metabolism: Clinical and Experimental, 2023
Orian S Shirihai, Anton Petcherski, Theodoros Kelesidis   +2 more
exaly  

Emtricitabine and tenofovir alafenamide vs emtricitabine and tenofovir disoproxil fumarate for HIV pre-exposure prophylaxis (DISCOVER): primary results from a randomised, double-blind, multicentre, active-controlled, phase 3, non-inferiority trial

Lancet, The, 2020
Moupali Das, Kenneth Mayer, Robert Grant   +2 more
exaly  

Effect of tenofovir alafenamide vs. tenofovir disoproxil fumarate on hepatocellular carcinoma risk in chronic hepatitis B

Journal of Viral Hepatitis, 2021
Jun Yong Park, Hye Won Lee, Jae Seung Lee   +2 more
exaly  

Switching from Tenofovir Disoproxil Fumarate to Tenofovir Alafenamide Significantly Worsens the Lipid Profile in a Real-World Setting

AIDS Patient Care and STDs, 2019
Pia Kivelä, Jussi Sutinen
exaly  

Tenofovir alafenamide versus tenofovir disoproxil fumarate, coformulated with elvitegravir, cobicistat, and emtricitabine, for initial treatment of HIV-1 infection: two randomised, double-blind, phase 3, non-inferiority trials

Lancet, The, 2015
Daniel Podzamczer, Paul Edward Sax, Scott Mccallister   +2 more
exaly  

Stability behaviour of antiretroviral drugs and their combinations. 4: Characterization of degradation products of tenofovir alafenamide fumarate and comparison of its degradation and stability behaviour with tenofovir disoproxil fumarate

Journal of Pharmaceutical and Biomedical Analysis, 2016
Saranjit Singh, Moolchand Kurmi, Vijaya Madhyanapu Golla   +2 more
exaly  

Tenofovir alafenamide for hepatitis B virus infection including switching therapy from tenofovir disoproxil fumarate

Journal of Gastroenterology and Hepatology (Australia), 2019
Sakura Kirino, Namiki Izumi, Mamoru Watanabe   +2 more
exaly  

Tenofovir Alafenamide Fumarate: A New Tenofovir Prodrug for the Treatment of Chronic Hepatitis B Infection

Journal of Infectious Diseases, 2017
Rafael Esteban, Mar Riveiro-Barciela, Maria Buti Ferret   +2 more
exaly  

Fanconi syndrome due to tenofovir disoproxil fumarate reversed by switching to tenofovir alafenamide fumarate in an HIV-infected patient

Therapeutic Advances in Infectious Disease, 2018
exaly